A Phase 1, Open-Label, Partially Randomized, 3-Part, Parallel Group Trial to Evaluate the Pharmacokinetic Profile of Glepaglutide (ZP1848) After a Single Intravenous Injection and After Multiple Subcutaneous Injections in Healthy Subjects

Trial Profile

A Phase 1, Open-Label, Partially Randomized, 3-Part, Parallel Group Trial to Evaluate the Pharmacokinetic Profile of Glepaglutide (ZP1848) After a Single Intravenous Injection and After Multiple Subcutaneous Injections in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Glepaglutide (Primary) ; Glepaglutide (Primary)
  • Indications Short bowel syndrome
  • Focus Pharmacokinetics
  • Sponsors Zealand Pharma
  • Most Recent Events

    • 12 Oct 2017 According to a Zealand Pharma media release, to date, 30 subjects have been dosed in this trial. Results from this trial are expected in Q1 2018.
    • 14 Sep 2017 New trial record
    • 13 Sep 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top